Aravive (ARAV) Competitors

$0.04 0.00 (0.00%)

As of 05/14/2026

ARAV vs. AIMDW, ALVOW, ACABW, RNA, and BFRIW

Should you buy Aravive stock or one of its competitors? MarketBeat compares Aravive with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aravive include Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Avidity Biosciences (RNA), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry.

How does Aravive compare to Ainos?

Ainos (NASDAQ:AIMDW) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

In the previous week, Ainos had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for Ainos and 0 mentions for Aravive. Ainos' average media sentiment score of 1.89 beat Aravive's score of 0.00 indicating that Ainos is being referred to more favorably in the media.

Company	Overall Sentiment
Ainos	Very Positive
Aravive	Neutral

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Ainos	N/A	N/A	N/A
Aravive	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$124.16K	N/A	N/A	N/A	N/A
Aravive	N/A	N/A	N/A	-$0.90	N/A

Summary

Ainos beats Aravive on 3 of the 5 factors compared between the two stocks.

How does Aravive compare to Alvotech?

Aravive (NASDAQ:ARAV) and Alvotech (NASDAQ:ALVOW) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Company	Net Margins	Return on Equity	Return on Assets
Aravive	N/A	N/A	N/A
Alvotech	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aravive	N/A	N/A	N/A	-$0.90	N/A
Alvotech	$586.32M	N/A	N/A	N/A	N/A

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Alvotech had 2 more articles in the media than Aravive. MarketBeat recorded 2 mentions for Alvotech and 0 mentions for Aravive. Alvotech's average media sentiment score of 1.44 beat Aravive's score of 0.00 indicating that Alvotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Aravive	Neutral
Alvotech	Positive

Summary

Alvotech beats Aravive on 3 of the 5 factors compared between the two stocks.

How does Aravive compare to Atlantic Coastal Acquisition Corp. II?

Aravive (NASDAQ:ARAV) and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) are both pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

In the previous week, Aravive's average media sentiment score of 0.00 equaled Atlantic Coastal Acquisition Corp. II'saverage media sentiment score.

Company	Overall Sentiment
Aravive	Neutral
Atlantic Coastal Acquisition Corp. II	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aravive	N/A	N/A	N/A	-$0.90	N/A
Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Aravive	N/A	N/A	N/A
Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Aravive beats Atlantic Coastal Acquisition Corp. II on 2 of the 2 factors compared between the two stocks.

How does Aravive compare to Avidity Biosciences?

Avidity Biosciences (NASDAQ:RNA) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

Aravive has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Aravive's return on equity of 0.00% beat Avidity Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%
Aravive	N/A	N/A	N/A

35.8% of Aravive shares are held by institutional investors. 3.8% of Avidity Biosciences shares are held by company insiders. Comparatively, 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Avidity Biosciences currently has a consensus target price of $66.95, suggesting a potential upside of 406.03%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Avidity Biosciences is more favorable than Aravive.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.37
Aravive	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Aravive has lower revenue, but higher earnings than Avidity Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	$18.62M	N/A	-$322.30M	N/A	N/A
Aravive	N/A	N/A	N/A	-$0.90	N/A

In the previous week, Avidity Biosciences had 5 more articles in the media than Aravive. MarketBeat recorded 5 mentions for Avidity Biosciences and 0 mentions for Aravive. Avidity Biosciences' average media sentiment score of 1.63 beat Aravive's score of 0.00 indicating that Avidity Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Avidity Biosciences	Very Positive
Aravive	Neutral

Summary

Avidity Biosciences beats Aravive on 7 of the 13 factors compared between the two stocks.

How does Aravive compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	N/A	N/A	N/A
Aravive	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	N/A	N/A	N/A	N/A
Aravive	N/A	N/A	N/A	-$0.90	N/A

In the previous week, Biofrontera had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for Biofrontera and 0 mentions for Aravive. Biofrontera's average media sentiment score of 1.87 beat Aravive's score of 0.00 indicating that Biofrontera is being referred to more favorably in the media.

Company	Overall Sentiment
Biofrontera	Very Positive
Aravive	Neutral

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Biofrontera beats Aravive on 3 of the 5 factors compared between the two stocks.

Get Aravive News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARAV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARAV vs. The Competition

Export

Metric	Aravive	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	N/A	$3.39B	$6.33B	$12.47B
Dividend Yield	N/A	2.31%	2.80%	5.28%
P/E Ratio	-0.04	18.03	20.07	25.23
Price / Sales	N/A	285.66	551.32	83.22
Price / Cash	N/A	124.05	43.04	56.04
Price / Book	N/A	6.63	9.83	6.91
Net Income	N/A	$24.40M	$3.56B	$334.11M
7 Day Performance	N/A	3.88%	0.25%	0.01%
1 Month Performance	N/A	-2.84%	-1.30%	1.17%
1 Year Performance	N/A	62.79%	33.61%	30.68%

Aravive Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARAV Aravive	N/A	$0.04 flat	N/A	N/A	$0.00	N/A	N/A	20	High Trading Volume
AIMDW Ainos	N/A	$0.08 +15.9%	N/A	-21.7%	$0.00	$124.16K	N/A	40	Positive News Gap Down
ALVOW Alvotech	N/A	$0.25 flat	N/A	-89.8%	$0.00	$586.32M	N/A	4	Positive News Short Interest Decrease Gap Down
ACABW Atlantic Coastal Acquisition Corp. II	N/A	$0.00 flat	N/A	N/A	$0.00	N/A	N/A	15
RNA Avidity Biosciences	2.3943 of 5 stars	$13.30 +1.2%	$69.42 +422.0%	-54.3%	$0.00	$18.62M	N/A	190	News Coverage Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARAV) was last updated on 5/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aravive (ARAV) Competitors